Windtree Therapeutics Inc (AKA: DIS~Discovery Laboratories Inc) Profile last edited on: 12/2/2023
CAGE: 5EKW9
UEI: MLFQZEK9E745
Business Identifier: Advancing late-stage interventions for acute cardiovascular disorders to treat patients in moments of crisis 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 01
County: Bucks
Congr. District: 01
County: Bucks
Public Profile
Formerly operating as Discovery Laboratories (NASDAQ:DIS), Windtree Therapeutics Inc. (NASDAQ:WINT) is a biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications. The company's proprietary KL4 surfactant technology platform involves a synthetic, peptide-containing surfactant that is structurally similar to human pulmonary surfactant. Windtree's technology also involves novel drug-delivery systems that are developed to enable noninvasive administration of aerosolized KL4 surfactant. With this technology initially aimed at improving the management of respitatory distress syndrome (RDS) in premature infants, the company's goal is to eventually utilize its technology to address a variety of respiratory diseases for which there are few or no approved therapies. In december 2018, WindtreePublicly traded respiratory-focused. Windtree Therapeutics Inc. acquired private cardiovascular disease-focused CVie Therapeutics Ltd. in a stock swap.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
20-24Revenue Range
2M-2.5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : WINTIP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2018 | 2 | NIH | $5,105,805 | |
| Project Title: Development &Utilization of a Novel Aerosol-Generating Technology to Deliver Luc | ||||
| 2016 | 2 | NIH | $3,577,799 | |
| Project Title: Kl4 Surfactant to Mitigate Radiation-Induced Lung Injury | ||||
| 2015 | 1 | NIH | $225,000 | |
| Project Title: K L Surfactant Aerosol to Reduce Influenza Lung Injury | ||||
| 2002 | 2 | NIH | $1,049,116 | |
| Project Title: Advanced Therapy For Acute Respiratory Distress Syndrome | ||||
Key People / Management
Craig E Fraser -- President and CEO
Robert Capetola -- former President
Diane Carman Esq -- SENIOR VICE PRESIDENT and GENERAL COUNSEL
Russell Clayton -- Senior Vice President of Research and Development
Kathryn A Cole -- Senior Vice President, Human Resources
John Cooper -- Former President and CEO, CFO
George Cox -- VP of Technical Operations
Eric L Curtis -- Sr. VP & COO
Ronald L Dundore -- Exec. Director of Regulatory Affairs & Quality
John P Hamill -- Sr. VP, CFO & Corp. Sec.
Thomas Miller -- Senior Vice President, and Chief Operating Officer
Masa Nakatsu -- Founder
Pratap Paruchuru -- Exec. Director of Clinical Development
Tracy Rarick -- Head of Operations & Program Management
Robert Segal
Steve Simonson -- Senior Vice President and Chief Medical Officer
Steven G Simonson -- Chief Development Officer And Senior VP
John Tattory -- Senior VP and CFO
Mary Templeton -- Senior Vice President, General Counsel, and Corporate Secretary
Lawrence A Weinstein -- Vice President, Medical Device Development
Thomas E Wiswell
Robert Capetola -- former President
Diane Carman Esq -- SENIOR VICE PRESIDENT and GENERAL COUNSEL
Russell Clayton -- Senior Vice President of Research and Development
Kathryn A Cole -- Senior Vice President, Human Resources
John Cooper -- Former President and CEO, CFO
George Cox -- VP of Technical Operations
Eric L Curtis -- Sr. VP & COO
Ronald L Dundore -- Exec. Director of Regulatory Affairs & Quality
John P Hamill -- Sr. VP, CFO & Corp. Sec.
Thomas Miller -- Senior Vice President, and Chief Operating Officer
Masa Nakatsu -- Founder
Pratap Paruchuru -- Exec. Director of Clinical Development
Tracy Rarick -- Head of Operations & Program Management
Robert Segal
Steve Simonson -- Senior Vice President and Chief Medical Officer
Steven G Simonson -- Chief Development Officer And Senior VP
John Tattory -- Senior VP and CFO
Mary Templeton -- Senior Vice President, General Counsel, and Corporate Secretary
Lawrence A Weinstein -- Vice President, Medical Device Development
Thomas E Wiswell
